Life-cycle development Helsinn Group announces AKYNZEO® (fosnetupitant/palonosetron) injection is now available in a ready-to-use vial in the US
Corporate Helsinn closes financing agreement with BancaStato to support business objectives and growth
Life-cycle development Helsinn announces publication of data evaluating impact of AKYNZEO® (fosnetupitant/palonosetron) on treatment outcomes and healthcare costs
Life-cycle development Helsinn announces publication of new data evaluating impact of NEPA (netupitant/palonosetron) on hospital costs
Life-cycle development Helsinn publishes results from a secondary analysis of a Phase 3 trial in patients with CINV in The Oncologist
